Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.

[1]  Ron Marcus.  Bristol Myers-Squibb , 2012, Schizophrenia Research.

[2]  C. Barrios,et al.  Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma , 2012, Cancer.

[3]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Collier,et al.  An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  W. Gradishar,et al.  A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC). , 2009 .

[7]  J. Baselga,et al.  SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC). , 2009 .

[8]  T. Yankeelov,et al.  NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  U. Harmenberg,et al.  Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Brown,et al.  7122 Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mRCC): preliminary results , 2009 .

[11]  J. Bergh,et al.  Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. , 2009, The American journal of pathology.

[12]  J. Blay,et al.  Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. , 2009, European journal of cancer.

[13]  Allen S Melemed,et al.  Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Berrino,et al.  Serum Insulin-Like Growth Factor-I and Platelet-Derived Growth Factor as Biomarkers of Breast Cancer Prognosis , 2008, Cancer Epidemiology Biomarkers & Prevention.

[15]  H. Rugo,et al.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Lyndsay Harris,et al.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[18]  Jung Hun Song,et al.  An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. , 2006, The Journal of clinical endocrinology and metabolism.

[19]  O. Potapova,et al.  Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248 , 2006, Molecular Cancer Therapeutics.

[20]  N. Pryer,et al.  Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. , 2003, Molecular cancer therapeutics.

[21]  M. Heinrich,et al.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.

[22]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[23]  N. Pryer,et al.  SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. , 2003, Molecular cancer therapeutics.

[24]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[25]  L. Berlin,et al.  Standard of care. , 1998, AJR. American journal of roentgenology.

[26]  C. Hudis,et al.  Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[28]  N. Pryer,et al.  SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model , 2004, Clinical & Experimental Metastasis.

[29]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.